SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) — Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, today announced positive Phase 1 results for its investigational Wharton’s Jelly-derived mesenchymal stem cell (WJ-MSC) therapy for neonatal brain injury. The therapy, co-developed with South Korea-based Medinno Inc., is being developed to treat intraventricular hemorrhage (IVH) and hypoxic-ischemic encephalopathy (HIE), two severe neurological conditions in newborns associated with high rates of mortality and long-term disability.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
